ArticleDiscover oncology2025
Construction of a hepatocellular carcinoma prognostic model based on the long non-coding RNA RHPN1-AS1.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundSeveral long non-coding RNAs (lncRNAs) have been identified as oncogenic factors in hepatocellular carcinoma (HCC). This study aims to investigate the biological function and prognostic value of lncRNA RHPN1-AS1 in HCC.
methodsHCC data were drawn from TCGA database. Coexpression, enrichment, and immune infiltration analyses were performed to identify the roles and mechanisms of RHPN1-AS1 in HCC. Kaplan‒Meier analysis was used to determine overall survival (OS) and progression-free survival (PFS). Univariate and multivariate Cox regression analyses were employed to discover independent prognostic indicators. A prognostic nomogram was established and validated.
resultsThe expression of RHPN1-AS1 was significantly upregulated in HCC samples, and was associated with poor OS and PFS. Univariate Cox regression analysis demonstrated that RHPN1-AS1, AJCC stage, T stage, and M stage were correlated with OS. In multivariate Cox regression analysis, RHPN1-AS was significantly linked to HCC prognosis. The predictive model based on RHPN1-AS1 and clinical factors reached good accuracy. In addition, RHPN1-AS1 was positively co-expressed with TONSL, CHRAC1, JRK, RECQL4, STK3, and CYHR1. Functional enrichment analysis of RHPN1-AS1 co-expressed genes were indicated significant involvement in the cell cycle, DNA replication, and double-strand break repair.
conclusionsLncRNA RHPN1-AS1 was identified as a potential independent prognostic indicator for HCC patients. A prognostic nomogram integrating RHPN1-AS1 expression and T and M stage was constructed to predict the survival of HCC patients. Furthermore, our findings suggested the involvement of the cell cycle in the action of RHPN1-AS1, providing new insights into the molecular mechanism underlying HCC progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.